The 5-year incidence of male breast cancer in Southwest of China from 2007 to 2011

Jin, Liangbin; Lü, Linyuan; Kong, Lingquan; Bai, Yang; Yao, Zi-xiang; Ji, Guangyan; Liu, Shengchun; Ren, Guosheng; Wu, Kainan; Tang, Hua; Mao, Deqiang

doi:10.1007/s10330-013-1234-7

Cited by 3 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certainly, various tumor related factors may also be related with liver dysfunction of breast cancer. This hypothesis was enlightened in our previous study about incidence of male breast cancer in Southwest of China, with a result that male breast cancer accounted for 1.96% to 6.5% (with the mean value of 2.9%) of breast cancers in Southwest of China from 2007 to 2011 and revealed that male breast cancer in Southwest of China was higher than that in United States(1%) [ 31 ]. So if oncogenesis of HBV in breast cancer functions through the impact on estrogen, and estrogen was also an important risk factor in the etiology of male breast cancer [ 32 ], males with an innate low-level of hormone may be more prone of having breast carcinoma through HBV infection than women.…”

Section: Discussionmentioning

confidence: 99%

“…So if oncogenesis of HBV in breast cancer functions through the impact on estrogen, and estrogen was also an important risk factor in the etiology of male breast cancer [ 32 ], males with an innate low-level of hormone may be more prone of having breast carcinoma through HBV infection than women. In addition, high HBV endemicity was more pronounced among males in china [ 33 ], so it is proved by our previous study that the rate of male breast cancer among all the breast cancers was relatively higher in Southwest of China [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical study on the relationship between hepatitis B virus infection and risk of breast cancer: a large sized case-control and single center study in southwest of China

et al. 2017

View full text Add to dashboard Cite

PurposeChronic hepatitis C virus (HCV) infection is reported to be associated with early-onset breast cancer, while, as a hepadnavirus, hepatitis B virus(HBV) infection is more common than HCV in China. In this article, it is aimed to study the relationship between HBV infection and risk of breast cancer in China.MethodsThe clinical data of 2452 cases of initially diagnosed breast cancer and 1926 cases of benign breast disease (as controls) with the consecutive reports of HBV serological markers and liver function tests, available in the Electronic Medical Records of the Breast Cancer Center of Chongqing, the southwest of China, from January 2011 to March 2015, were collected for analysis.ResultsThe average age of the initially diagnosed breast cancer patients was 50.3±11.3 years with the age peaking about 40- 49yeaers (39.7%). The positive rate (8.2%) of hepatitis B surface antigen in breast cancer patients was relatively higher than that (7.8%) in controls (P>0.05). While, the positive rate (66.4%)of hepatitis B core antibody in breast cancer patients was significantly higher than that (53.7%) in controls (P<0.05), so were the similar results in the age groups of 40-49 years, after multiple layer analysis stratified by age and compare HBV markers adjusting age with binary logistic regression. Meanwhile, the status of albumin, aminotransferase and aspartate transaminase (41.4 g/L, 22.9 U/L, 22.0 U/L) in breast cancer patients were significantly poorer than those (44.1 g/L,16.8 U/L, 19.2 U/L) in controls (P<0.05).ConclusionsExposure to HBV infection may be a risk factor for breast cancer and may be also related to the earlier age onset of breast cancer (peaked around 40-49 years) among Chinese females.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical study on the relationship between hepatitis B virus infection and risk of breast cancer: a large sized case-control and single center study in southwest of China

et al. 2017

View full text Add to dashboard Cite

show abstract

“… 59 The epidemiology of breast cancer in Chinese males has not been frequently studied. One study reported that the incidence rate of male breast cancer in southwest People’s Republic of China (Chongqing Province) changed from 1.96% in 2007 to 6.5% in 2010, 61 suggesting an increasing trend.…”

Section: Letrozole In People’s Republic Of Chinamentioning

confidence: 99%

Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective

2016

OTT

View full text Add to dashboard Cite

The incidence rate of breast cancers in People’s Republic of China has increased in the last decade, and many cases are responsive to hormone therapies. The third-generation aromatase inhibitor letrozole inhibits estrogen production, and is more efficacious than the estrogen receptor inhibitor tamoxifen. In recent years, letrozole has been widely used to treat postmenopausal breast cancers in People’s Republic of China. Also, metastatic, premenopausal, and male breast cancers have been effectively treated by a combination of letrozole with cytotoxic, radiation, or other therapies. In this review, we provide a perspective and summary of recent advances in the use of letrozole for breast cancer in Chinese patients.

show abstract

“…In Korea, the 5-year overall survival rate was lower for MBC than for FBC (76.2% vs 88.9%) [8], but a study in Hong Kong suggested that MBC did not show lower survival until 10 years later [9]. Previous studies in China mainland were not convincing enough because of the sample size (ranging from 24 to 106 male patients) [10][11][12]. Furthermore, healthcare utilization of MBC is of little concern so far with only one study globally [13].…”

mentioning

confidence: 99%

Do ethnic disparities exist in disease burden and healthcare utilization of male breast cancer: a 9-year cohort study of 18.19 million adults in China

Chen,

Qiao,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background As a rare disease, male breast cancer (MBC) is of increasing concern in China. Whether health inequalities of disease burden and healthcare utilization exist by ethnicity in male breast cancer remains unclear. We aim to measure disease burden and healthcare utilization by ethnicity among male breast cancer patients in China. Methods A retrospective cohort study was established during 2012–2021 based on Inner Mongolia Regional Health Information Platform. Disease burden including incidence, 5-year prevalence, mortality, survival rate, and medical cost were analyzed. Results Among 630 participants (mean [SD] age, 59.4 [13.1] years), age-standardized rates of incidence were 1.2 (95% CI: 0.4–2.1) per 100000. All-cause mortality was 50.8 per 1000 person-years (95% CI: 42.4–60.4) but breast cancer-specific mortality was 5.5 per 1000 person-years (95% CI: 3.0-9.3). Regarding ethnicity, Mongolian had a higher age-standardized 5-year prevalence rate than Han (3.2[95% CI: 2.5-4.0] vs 2.3[95% CI: 1.7-3.0], P = 0.016), but no significant differences existed in incidence rates, survival rates, and risk of all-cause and breast cancer-specific mortality. Patients residing in areas of lower GDP level were associated with increased breast-cancer specific mortality (HR, 22.5, [95% CI: 1.6–325.0]; P = 0.022). Conclusions This study revealed a moderate disease burden and relatively lower healthcare utilization for male breast cancer in Inner Mongolia, China. No significant ethnic disparities existed in disease burden and healthcare utilization. However, we still demanded for increasing attention to male breast cancer due to the crucial influence of economic factors on potential ethnic disparities.

show abstract

The 5-year incidence of male breast cancer in Southwest of China from 2007 to 2011

Cited by 3 publications

References 24 publications

Clinical study on the relationship between hepatitis B virus infection and risk of breast cancer: a large sized case-control and single center study in southwest of China

Clinical study on the relationship between hepatitis B virus infection and risk of breast cancer: a large sized case-control and single center study in southwest of China

Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective

Do ethnic disparities exist in disease burden and healthcare utilization of male breast cancer: a 9-year cohort study of 18.19 million adults in China

Contact Info

Product

Resources

About